NYSE American: IGC

Investor Relations

Committed to transparency and the advancement of next-generation therapies for neurodegenerative diseases through rigorous science and AI-driven innovation.

IGC-Pharma-Alzheimer-Therapy-Cognitive-Pathology
IGC Pharma Advances IGC-AD1 as a Potential Alzheimer’s Therapy Addressing Cognitive Impairment and Underlying Disease Pathology  
Read More →
IGC Pharma-Phase2- Results-Cognitive-Benefits-Alzheimer-Th
IGC Pharma Announces Additional Phase 2 Interim Results Highlighting Cognitive Benefits of IGC-AD1 for Alzheimer’s Treatment  
Read More →
IGC-Pharma-Alzheimer-Fiscal-Report-TN
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in its Alzheimer’s Pipeline
Read More →
IGC Pharma-IMS-Spotlight-Interview-Alzheimer-Weight-Loss-Therapies-TN
IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
Read More →
IGC-Pharma-Two-Patients-Baycrest-Phase-2-Alzheimer
IGC Pharma Announces Patient Enrollment at Toronto’s Baycrest in Phase 2 Trial Investigating IGC-AD1
Read More →
IGC-Pharma-Wins-2-Awards-Phase-1-NIA-AI-Prepare
IGC Pharma Wins 2 Awards in Phase 1 of NIA’S AI PREPARE Challenge, Advancing Alzheimer’s Early Prediction Research
Read More →
tumbnail-Additional-Data-Supporting-IGC-AD1-Dual-Purpos-Alzheimer-Treatment
IGC Pharma Announces Additional Data Supporting IGC-AD1 as an Alzheimer’s Treatment
Read More →
18-advances-IGC-AD1-clinical-trials-potential-anti-amyloid-AD-Tumbnail
IGC Pharma Advances IGC-AD1 Toward Clinical Trials as a Potential anti-Amyloid Plaque Treatment for Alzheimer’s Disease
Read More →
IGC-Pharma-Results-Stockholders-2024-Thumbnail
IGC Announces Results of its 2024 Annual Stockholders Meeting
Read More →
16-New-Molecule-IGC-1C-Thumbnail
IGC Pharma Announces Research Demonstrating New Molecule IGC-1C Targets Tau Protein in Alzheimer’s Disease
Read More →
tumbnail, GLP-1, GIP, Weight loss, insulin, diabetes, metabolic disorders, agonist, antagonist
IGC Pharma Expands Drug Portfolio to Metabolic Disorders with IGC-1A, A Potential New GLP-1 Agonist
Read More →
Tumbnail-2-Equity-Analyst-Coverage-by-Alliance-Global-Partners
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) with a “Buy” Recommendation and $3.50 Price Target
Read More →
TGR-63-demostrate-blood-brain-barrier-IGCPharma
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
Read More →
IGC-TGR63-preclinical-results-show-reduction-amyloid-plaque
IGC Pharma’s TGR-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer’s Disease
Read More →
IGC-Reports-Financial-Results-Fiscal-Year
IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
Read More →
IGCPharma Participate in Fireside
IGC Pharma to Participate in Fireside Chat with Ascendiant Capital Markets
Read More →